{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:35:08Z","timestamp":1794346508962,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ygyno.2022.05.025","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:34:00Z","timestamp":1654648440000},"page":"284-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?"],"prefix":"10.1016","volume":"166","author":[{"given":"P.","family":"Lof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van de Vrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Korse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.J.M.","family":"van Gent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Mom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.M.F.","family":"Rosier - van Dunn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"van Baal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Verhoeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.J.","family":"Hermsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Verbruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hemelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.G.","family":"van de Swaluw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Knipscheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.F.","family":"Huirne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.R.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2011.03.005","article-title":"Should we centralise care for the patient suspected of having ovarian malignancy?","volume":"122","author":"Geomini","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.05.025_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2008.11.011","article-title":"Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands","volume":"112","author":"Vernooij","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.05.025_bb0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ygyno.2007.02.030","article-title":"The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review","volume":"105","author":"Vernooij","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.05.025_bb0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ygyno.2012.04.012","article-title":"Centralisation of services for gynaecological cancers - a Cochrane systematic review","volume":"126","author":"Woo","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0025","author":"Ultrasound models by The International Ovarian Tumor Analysis (IOTA) group"},{"issue":"10","key":"10.1016\/j.ygyno.2022.05.025_bb0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.05.025_bb0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/uog.12440","article-title":"Intensive training program for ultrasound diagnosis of adnexal masses: protocol and preliminary results","volume":"42","author":"Alc\u00e1zar","year":"2013","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/uog.6443","article-title":"Ultrasound methods to distinguish between malignant and benign adnexal masses in the hands of examiners with different levels of experience","volume":"34","author":"Van Holsbeke","year":"2009","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.05.025_bb0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0043-113819","article-title":"Simple rules, not so simple: the use of international ovarian tumor analysis (IOTA) terminology and simple rules in inexperienced hands in a prospective multicenter cohort study","volume":"38","author":"Meys","year":"2017","journal-title":"Ultraschall Med."},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/172460089801300411","article-title":"CA 125 in benign gynecological conditions","volume":"13","author":"Meden","year":"1998","journal-title":"Int. J. Biol. Markers"},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration","volume":"75","author":"Buamah","year":"2000","journal-title":"J. Surg. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2022.05.025_bb0060","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11596-020-2163-7","article-title":"Ultrasound features improve diagnostic performance of ovarian cancer predictors in distinguishing benign and malignant ovarian tumors","volume":"40","author":"Chen","year":"2020","journal-title":"Curr. Med. Sci."},{"issue":"5","key":"10.1016\/j.ygyno.2022.05.025_bb0070","article-title":"Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses","volume":"49","author":"Aslan","year":"2020","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0075","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/aogs.14224","article-title":"The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis","volume":"100 (10)","author":"Olsen","year":"2021","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1503\/cmaj.050090","article-title":"Evidence of bias and variation in diagnostic accuracy studies","volume":"174","author":"Rutjes","year":"2006","journal-title":"Cmaj."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cca.2014.08.020","article-title":"Human epididymis protein 4: factors of variation","volume":"438","author":"Ferraro","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"11","key":"10.1016\/j.ygyno.2022.05.025_bb0090","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1055-9965.EPI-14-0447","article-title":"HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review","volume":"23","author":"Karlsen","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0015-0282(97)81482-3","article-title":"Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors","volume":"68","author":"van Noord","year":"1997","journal-title":"Fertil. Steril."},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.12.028","article-title":"Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age","volume":"206","author":"Moore","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0105","unstructured":"Electro-chemiluminescence immunoassay (ECLIA) for the quantitative determination of humanepididymal protein 4 (HE4) in serum and plasma."},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1068-607X(98)00046-8","article-title":"New reference levels for CA125 in pre- and postmenopausal women","volume":"5","author":"Nguyen","year":"1998","journal-title":"Prim. Care Update Ob. Gyns."},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2022.05.025_bb0120","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1007\/s13277-014-1945-6","article-title":"HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer","volume":"35","author":"Ortiz-Munoz","year":"2014","journal-title":"Tumour Biol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.05.025_bb0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/humupd\/dmt059","article-title":"Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis","volume":"20","author":"Kaijser","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.ygyno.2022.05.025_bb0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2015.11.005","article-title":"Impact of surgical staging on prognosis in patients with borderline ovarian tumours: a meta-analysis","volume":"54","author":"Shim","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2022.05.025_bb0135","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/IGC.0000000000000722","article-title":"The evaluation of risk factors associated with relapse and recurrence of borderline ovarian tumors with long-term follow-up","volume":"26","author":"Sobiczewski","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2022.05.025_bb0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/bjc.2014.648","article-title":"Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study","volume":"112","author":"Trillsch","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0145","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2016.01.007","article-title":"Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis","volume":"58","author":"Meys","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/uog.12308","article-title":"Risk of malignancy in unilocular cysts: a study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature","volume":"41","author":"Valentin","year":"2013","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2022.05.025_bb0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10815-007-9128-7","article-title":"Transvaginal ultrasound assessment of the premenopausal ovarian mass","volume":"24","author":"Cohen","year":"2007","journal-title":"J. Assist. Reprod. Genet."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0175","article-title":"Laparoscopy versus laparotomy for benign ovarian tumour","volume":"2","author":"Medeiros","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.ygyno.2022.05.025_bb0180","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/uog.17225","article-title":"Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods","volume":"49","author":"Meys","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.05.025_bb0185","article-title":"Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study","volume":"370","author":"Van Calster","year":"2020","journal-title":"Bmj."},{"issue":"9","key":"10.1016\/j.ygyno.2022.05.025_bb0190","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2022.05.025_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12916-016-0667-6","article-title":"Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening","volume":"14","author":"Cohen","year":"2016","journal-title":"BMC Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822003365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822003365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:01:31Z","timestamp":1758772891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822003365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0090825822003365"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.05.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}